On June 10, 2024, Michael A. Jacobsen informed the Board of Directors of Omeros Corporation (“Omeros” or the “Company”) of his intention to retire from his positions as the Company’s Vice President, Finance, Chief Accounting Officer and Treasurer, effective June 30, 2024.
On June 7, 2024, Michael Hartmeier submitted his resignation as a member of the Board of Directors (the "Board") of Full House Resorts, Inc. (the "Company"), effective immediately.
Departed
Mark Mizicko
Executive Vice President and Chief Commercial Officer
Executive Vice President and Chief Commercial Officer, Mr. Mark Mizicko notified the Board of Directors of his intent to retire from his position at the Company effective as of June 14, 2024.
Upon the closing of the Offering and the resulting reduction in the outstanding shares of Class C common stock and Class D common stock, on June [12], 2024, Sean Sullivan, who served as the remaining Class C Director, resigned from the Board in accordance with the Certificate of Incorporation and the Stockholders Agreement.
On June 10, 2024, Anat Ashkenazi, a director of Maravai LifeSciences Holdings, Inc. (the “Company”), informed the Board of Directors of the Company (the “Board”) that she plans to resign from the Board effective as of July 31, 2024, in consideration of the time commitments associated with her pending appointment as Chief Financial Officer of Alphabet Inc.
On June 9, 2024, Mr. Scipio “Max” Carnecchia tendered his resignation as a member of the Board of Directors of Mitek Systems, Inc. (the “Company”) effective immediately.
On June 5, 2024, Christian Lown, Chief Financial Officer (CFO) of Freddie Mac (formally the Federal Home Loan Mortgage Corporation) notified Freddie Mac of his intention to step down from his position as CFO, effective June 28, 2024.
On June 11, 2024, in connection with the closing of the Transaction, Lawrence A. Mendelsohn resigned from his position as Chief Executive Officer of the Company, and the Company appointed Michael Nierenberg to serve as its Chief Executive Officer.
On June 9, 2024, Barbara Nelson, a member of the Board of Directors of the Company (the “Board”), the Chair of the Nominating and Governance Committee of the Board and a member of the Audit Committee of the Board, notified the Company of her decision not to stand for reelection when her current term expires at the Company’s 2024 Annual Meeting of Stockholders.
On June 6, 2024, Mr. Charles “Chuck” L. Prow resigned from his position as a Class I Director of the Company’s Board of Directors, effective June 16, 2024.
Departed
Dennis L. Walsh
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
James A. Bristol
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Ron Squarer
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Frank S. Friedman
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Patricia L. Allen
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Susan L. Kelley
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
Edward J. Benz, Jr.
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
Departed
John R. Martin
Director
Deciphera Pharmaceuticals, Inc.
Effective
2024-06-11
Successor
Toichi Takino and Masayuki Tanigawa
Filed
June 11, 2024, 7:59 PM ET
Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera
On June 7, 2024, Jonathan Coslet notified Cushman & Wakefield plc (the “Company”) of his decision to resign from the Board, effective immediately, which the Board accepted.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Mario Dell’Aera Jr., David Golden, Michael Huseby, Steven Panagos, Vice Admiral John Ryan, Rory Wallace, and Raphael Wallander resigned from the Company’s Board of Directors.
Hwan-Yoon F. Chung advised EnerSys’ board of directors (the “Board”) of his decision not to stand for re-election to the Board for the upcoming annual meeting of the stockholders in 2024 (the “2024 Annual Meeting”) in order to focus on his other commitments.
Departed
Rabia Gurses Ozden, M.D.
Director
Adverum Biotechnologies, Inc.
Effective
2024-06-10
Successor
Szilárd Kiss, M.D.
Filed
June 11, 2024, 7:59 PM ET
Dr. Ozden notified the Board of her decision to resign from the Board and the Research and Development Committee of the Board, effective June 10, 2024.
Adam Koppel notified Solid Biosciences Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), effective as of June 11, 2024.
On June 6, 2024, Dr. Whitney Haring-Smith, notified the Company of his decision to resign from the board of directors of the Company (the “Board”) effective immediately.
On June 9, 2024, Li Han, a member of the Board of Directors (the “Board”) of Faraday Future Intelligent Electric Inc., a Delaware corporation (the “Company”), notified the Board that she will resign as a director of the Company for personal reasons, effective immediately.
Departed
Justin M. Grow
Executive Vice President and Chief Administrative Officer
DELTA APPAREL, INC
Effective
2024-06-05
Filed
June 11, 2024, 7:59 PM ET
On June 5, 2024, Justin M. Grow, Executive Vice President and Chief Administrative Officer amended the effective date of his resignation to June 5, 2024.
Departed
Matthew J. Miller
President of Delta Group
DELTA APPAREL, INC
Effective
2024-06-06
Filed
June 11, 2024, 7:59 PM ET
On June 6, 2024, Matthew J. Miller, President of Delta Group submitted his resignation effective immediately.
Ms. McClure will step down as Chief Financial Officer and member of the Global Management Committee on November 30, 2024, and retire on March 31, 2025.
Departed
Harald Reinhart
President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.
On June 5, 2024, Randy D. Uglem, our current President and Chief Executive Officer, informed us of his intent to resign from all positions with the Company, effective July 1, 2024.
On June 10, 2024, Murray Roos resigned from the Board of Directors (the " Board ") of Tradeweb Markets Inc. (the " Company "), effective as of such date.
Departed
Shanoop Kothari
Chief Executive Officer
LUXURBAN HOTELS INC.
Effective
2024-06-10
Successor
Robert Arigo
Filed
June 11, 2024, 7:59 PM ET
Mr. Kothari’s employment being terminated by the Company without cause and principally based on the Company’s desire to bring significant hotel operations and field experience to the role of Chief Executive Officer.
Departed
Michael A. Haberman
Executive Vice President of the Industrial Equipment Division
On June 10, 2024, Alamo Group Inc. (the “Company”) issued a press release announcing the retirement of Executive Vice President of the Industrial Equipment Division of the Company, Michael A. Haberman, effective August 6, 2024.
On June 5, 2024, Mr. Ronen Faier notified the Board of Directors (the “Board”) of SolarEdge Technologies, Inc. (the “Company”) of his intention to retire as Chief Financial Officer of SolarEdge Technologies, Inc. (the “Company”) on a date to be agreed on between Mr. Faier and the Board following an approximately three-month transition period.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.